Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center
Authors:
Abstract
Background: Genetic assessment in Ashkenazi Jewish (AJ) patients often is limited to BRCA1/2 founder mutation testing. With access to time‐efficient and cost‐efficient multigene panel testing, some advocate expanding genetic testing in this population. However, to the best of the authors’ knowledge, rates of nonfounder BRCA1/2 mutations and mutations in cancer‐associated genes other than BRCA1/2 among AJ are not known. In the current study, the authors sought to assess the prevalence of mutations other than BRCA1/2 founder mutations among AJ patients undergoing genetic assessment. Methods: The authors reviewed the medical records for all AJ patients who underwent genetic assessment at a single institution between June 2013 and December 2016. Mutations were categorized as 1) BRCA1/2 AJ founder mutations ( BRCA1 185delAG, BRCA1 5382insC, or BRCA2 6174delT); 2) nonfounder BRCA1/2 mutations; or 3) mutations in non‐ BRCA1/2 cancer‐associated genes. Results: A total of 732 AJ patients underwent genetic assessment. Of these, 371 patients (51%) had a personal history of breast or ovarian cancer, 540 patients (73.8%) had a family history of breast cancer, and 132 patients (18%) had a family history of ovarian cancer. In the study population, 101 patients (13.8%) were found to have a pathogenic mutation, 78 patients (10.7%) had a BRCA1/2 founder mutation, 3 patients (0.4%) had a nonfounder BRCA1/2 mutation, and 20 patients (2.7%) had a mutation in a non‐ BRCA1/2 cancer‐associated gene. Non‐ BRCA1/2 cancer‐associated genes harboring mutations included RAD51D , TP53 , mutS homolog 6 ( MSH6 ), checkpoint kinase 2 (CHEK2), adenomatous polyposis coli ( APC ), and Fanconi anemia group C protein ( FANCC ). Conclusions: Among AJ patients found to have a pathogenic mutation on genetic assessment, approximately 22.8% had a mutation that would be missed with BRCA1/2 AJ founder mutation testing. Comprehensive multigene panel sequencing can provide clinically relevant genetic information for AJ patients and should be considered for genetic assessment in this population.Keywords
This publication has 30 references indexed in Scilit:
- The APC p.I1307K polymorphism is a significant risk factor for CRC in average risk Ashkenazi JewsEuropean Journal of Cancer, 2013
- Exome Sequencing Identifies Rare Deleterious Mutations in DNA Repair Genes FANCC and BLM as Potential Breast Cancer Susceptibility AllelesPLOS Genetics, 2012
- Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutationsFamilial Cancer, 2011
- BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patientsBritish Journal of Cancer, 2011
- Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancerCancer, 2011
- Meta-Analysis of BRCA1 and BRCA2 PenetranceJournal of Clinical Oncology, 2007
- Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish populationHuman Molecular Genetics, 2005
- Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2Science, 2003
- A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer familiesHuman Mutation, 2002
- BRCA1 and BRCA2 Mutation Analysis of 208 Ashkenazi Jewish Women with Ovarian CancerThe American Journal of Human Genetics, 2000